Cession Oncology

Cession Oncology is a late preclinical-stage biotechnology company advancing cutting-edge therapies to transform the treatment of pancreatic cancer and other deadly cancers. Our proprietary nanoparticle technology, developed at Georgetown University Medical Center, has shown a remarkable ability to inhibit primary tumor growth and completely halt metastasis in pancreatic cancer models. We’ve built a world-class team with deep expertise spanning academia, industry, and investment.